Xin Lang Cai Jing·2026-01-12 12:58Core Viewpoint - Zhejiang Haixiang Pharmaceutical Co., Ltd. has signed an innovative drug cooperation agreement with Wanbangde Pharmaceutical Holdings Group's wholly-owned subsidiary, focusing on the development and commercialization of WP205 for ALS, with plans to expand into MCR-targeted small molecule peptide agonists [1][2]. Cooperation Agreement Details - Haixiang Pharmaceutical will provide a total of 150 million yuan in funding to Wanbangde Pharmaceutical in two phases: 120 million yuan (80%) within five working days of signing, and 30 million yuan (20%) after reaching an agreement with the FDA on the Phase III clinical plan or obtaining conditional market approval in China and the U.S. [1] - In return for its investment, Haixiang will receive 15% of the global commercialization profits from WP205, including 15% of net profits from product sales and third-party licensing [1]. - The agreement includes risk control clauses, allowing Haixiang to terminate the agreement if the Phase III clinical plan is not agreed upon by June 30, 2027, with a full refund of payments plus a 3% annual usage fee [1]. Market Context - ALS has a global average incidence rate of approximately 4.42 cases per 100,000 people, with an average survival period of 3-5 years post-diagnosis, indicating significant unmet clinical needs [2]. - In the U.S., the incidence rate is reported at 4.4 cases per 100,000, highlighting a substantial untapped market potential [2]. Strategic Significance - This collaboration will enhance Haixiang's positioning in the peptide drug sector, leveraging a funding cooperation model to participate in the innovative drug development for neurodegenerative diseases, creating a complementary advantage between industry and research [2]. - The agreement does not constitute a related party transaction or a major asset restructuring, thus not requiring approval from Haixiang's board or shareholders [3].